About 70 percent of Americans with history of heart disease, stroke take aspirin
the ONA take:
About 70% of Americans who have heart disease or a stroke regularly take low-dose aspirin, according to a report from the U.S. Centers for Disease Control and Prevention (CDC).
For the study, researchers from the U.S. CDC analyzed data from the 2013 Behavioral Risk Factor Surveillance System, which included patients surveyed via telephone from 20 states and the District of Columbia. They found that 70.8% of respondents take low-dose aspirin regularly. More importantly, nearly 94% of those with a history of heart problems reported taking low-dose aspirin regularly to prevent a heart attack
In addition, approximately 80% reported taking it for stroke prevention and 76% said they take it to prevent both. Only 4% of respondents reporting taking low-dose aspirin for pain relief only.
Mississippi had the highest aspirin use with 72% of patients with heart problems regularly taking low-dose aspirin. Missouri had the lowest with 44%. Researchers found the males, people 65 years and older, whites, and patients with at least two cardiac risk factors are more likely to take aspirin compared with other groups.
The findings suggest that clinicians should target patients reporting lower regular aspirin use like Hispanics, blacks, and those who did not attain a high school diploma.
About 70% of Americans who have heart disease or a stroke regularly take low-dose aspirin.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|